肿瘤(癌症)患者之家
首页
癌症知识
肿瘤中医药治疗
肿瘤药膳
肿瘤治疗技术
前沿资讯
登录/注册
VIP特权

文章目录

仙台病毒融合基因的肿瘤免疫治疗

Cancer immunotherapy using the Fusion gene of Sendai virus 

原文发布日期:2019-08-06 

英文摘要:

摘要翻译: 

原文链接:

文章:

仙台病毒融合基因的肿瘤免疫治疗

Cancer immunotherapy using the Fusion gene of Sendai virus 

原文发布日期:2019-08-06 

英文摘要:

Inactivated Sendai virus particle (or hemagglutinating virus of Japan envelope; HVJ-E) has been previously reported to possess antitumour properties that activate antitumour immunity. Two glycoproteins, fusion (F) and hemagglutinin-neuraminidase (HN), are present on the surface of HVJ-E. HN is necessary for binding to receptors such as acidic gangliosides, and F induces membrane fusion by associating with membrane lipids. We previously reported that liposomes reconstituted with F but not HN showed antitumour activity by inducing IL-6 secretion in dendritic cells (DCs), suggesting that F protein is capable of eliciting antitumour activity. Here, we attempted to deliver F gene into tumour tissue in mice by electroporation and demonstrated that F gene therapy retarded tumour growth, increased CD4+ and CD8+ T-cell infiltration into tumours and induced tumour-specific IFN-γ T-cell response. However, neutralisation of IL-6R signalling did not impact F plasmid-mediated antitumour effect. Instead, we found that F plasmid treatment resulted in a significant increase in the secretion of the chemokine RANTES (regulated upon activation, normal T cell expressed and secreted) by tumour-infiltrating T cells. Neutralising antibody against RANTES abolished the antitumour effect of F plasmid treatment in a dose-dependent manner. Thus, F gene therapy may show promise as a novel therapeutic for single or combined cancer immunotherapy. 

摘要翻译: 

既往研究表明,灭活仙台病毒颗粒(又称日本血凝病毒包膜;HVJ-E)具有激活抗肿瘤免疫的特性。HVJ-E表面存在两种糖蛋白:融合蛋白(F)和血凝素-神经氨酸酶(HN)。HN是结合酸性神经节苷脂等受体所必需的组分,而F蛋白通过与膜脂质结合诱导膜融合。我们前期研究发现,仅重构F蛋白(不含HN)的脂质体可通过诱导树突状细胞(DCs)分泌IL-6发挥抗肿瘤活性,提示F蛋白具备激发抗肿瘤效应的能力。本研究尝试通过电穿孔方式将F基因递送至小鼠肿瘤组织,证实F基因治疗可延缓肿瘤生长、增加CD4+和CD8+ T细胞在肿瘤中的浸润,并诱导肿瘤特异性IFN-γ T细胞应答。然而,IL-6R信号通路中和并未影响F质粒介导的抗肿瘤效应。进一步研究发现,F质粒处理可显著增加肿瘤浸润T细胞分泌趋化因子RANTES(活化调节趋化因子)。使用RANTES中和抗体能以剂量依赖性方式完全消除F质粒治疗的抗肿瘤效果。因此,F基因疗法有望成为单一或联合癌症免疫治疗的新型策略。

原文链接:

Cancer immunotherapy using the Fusion gene of Sendai virus 

相关文章

文章:肿瘤抗原优先来源于黑色素瘤和非小细胞肺癌中未突变的基因组序列
文章:年龄相关的烟酰胺腺嘌呤二核苷酸下降驱动CAR-T细胞衰竭
文章:MCSP+转移创始细胞在人类黑色素瘤转移定植早期激活免疫抑制
文章:脂质纳米颗粒递送合成抗原使实体瘤对car介导的细胞毒性敏感
文章:食管癌新辅助治疗中的进化和免疫微环境动力学
文章:CHD1缺失重编程srebp2驱动的胆固醇合成,在spop突变的前列腺肿瘤中促进雄激素响应性生长和去势抵抗
文章:对TIL细胞治疗无反应的转移性非小细胞肺癌患者的T细胞和新抗原保留受损的时间序列分析
文章:策展的癌细胞图谱提供了单细胞分辨率的肿瘤的全面表征
文章:以人群为基础的胶质瘤分子景观分析在青少年和年轻人揭示胶质瘤形成的见解
文章:肿瘤细胞上的PILRα与T细胞表面蛋白CD99相互作用抑制抗肿瘤免疫

……